RICTOR
Summary: RICTOR and MTOR (FRAP1; MIM 601231) are components of a protein complex that integrates nutrient- and growth factor-derived signals to regulate cell growth (Sarbassov et al., 2004 [PubMed 15268862]).[supplied by OMIM, Mar 2008].
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| RPTOR independent companion of MTOR complex 2 | MIM:609022 | Ensembl:ENSG00000164327 | HGNC:HGNC:28611 | PA165660455 | 5p13.1 |
Gene Categories:
CLINICALLY ACTIONABLEGO terms in RICTOR
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| BP | IEA | GO:0001938 | positive regulation of endothelial cell proliferation |
| BP | ISS | GO:0009792 | embryo development ending in birth or egg hatching |
| BP | IEA | GO:0010468 | regulation of gene expression |
| BP | IGI | GO:0018105 | peptidyl-serine phosphorylation |
| BP | IBA | GO:0030010 | establishment of cell polarity |
| BP | IEA | GO:0030838 | positive regulation of actin filament polymerization |
| BP | IBA | GO:0030950 | establishment or maintenance of actin cytoskeleton polarity |
| BP | IBA | GO:0031532 | actin cytoskeleton reorganization |
| BP | IMP | GO:0031532 | actin cytoskeleton reorganization |
| BP | IEA | GO:0031929 | TOR signaling |
| BP | IMP | GO:0032008 | positive regulation of TOR signaling |
| BP | TAS | GO:0032148 | activation of protein kinase B activity |
| BP | IBA | GO:0032956 | regulation of actin cytoskeleton organization |
| BP | IMP | GO:0032956 | regulation of actin cytoskeleton organization |
| BP | IEA | GO:0033135 | regulation of peptidyl-serine phosphorylation |
| BP | IBA | GO:0042325 | regulation of phosphorylation |
| BP | IEA | GO:0043087 | regulation of GTPase activity |
| BP | IEA | GO:0050727 | regulation of inflammatory response |
| BP | IEA | GO:0050731 | positive regulation of peptidyl-tyrosine phosphorylation |
| BP | IDA | GO:0051896 | regulation of protein kinase B signaling |
| BP | IBA | GO:0051897 | positive regulation of protein kinase B signaling |
| BP | IEA | GO:2000114 | regulation of establishment of cell polarity |
| CC | TAS | GO:0005829 | cytosol |
| CC | IBA | GO:0031932 | TORC2 complex |
| CC | IDA | GO:0031932 | TORC2 complex |
| MF | IPI | GO:0005515 | protein binding |
| MF | IBA | GO:0008047 | enzyme activator activity |
| MF | IPI | GO:0019901 | protein kinase binding |
| MF | IEA | GO:0043022 | ribosome binding |
Gene expression in normal tissue: RICTOR
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in RICTOR
| Database | Pathway ID | Pathway Des. |
|---|---|---|
| pid | cxcr3pathway | CXCR3-mediated signaling events |
| pid | cxcr4_pathway | CXCR4-mediated signaling events |
| pid | erbb1_downstream_pathway | ErbB1 downstream signaling |
| pid | ilk_pathway | Integrin-linked kinase signaling |
| pid | mtor_4pathway | mTOR signaling pathway |
| pid | pi3kciaktpathway | Class I PI3K signaling events mediated by Akt |
| kegg | hsa04150 | mTOR signaling pathway - Homo sapiens (human) |
| netpath | Pathway_EGFR1 | EGFR1 |
| netpath | Pathway_Ghrelin | Ghrelin |
| netpath | Pathway_Oncostatin_M | Oncostatin_M |
| wikipathways | WP1471 | Target Of Rapamycin (TOR) Signaling |
| wikipathways | WP2263 | Androgen Receptor Network in Prostate Cancer |
| wikipathways | WP2374 | Oncostatin M Signaling Pathway |
| wikipathways | WP3844 | PI3K-AKT-mTOR signaling pathway and therapeutic opportunities |
| wikipathways | WP3888 | VEGFA-VEGFR2 Signaling Pathway |
| wikipathways | WP3915 | Angiopoietin Like Protein 8 Regulatory Pathway |
| wikipathways | WP4011 | Steatosis AOP |
| wikipathways | WP437 | EGF-EGFR Signaling Pathway |
| reactome | R-HSA-1257604 | PIP3 activates AKT signaling |
| reactome | R-HSA-1280218 | Adaptive Immune System |
| reactome | R-HSA-162582 | Signal Transduction |
| reactome | R-HSA-1643685 | Disease |
| reactome | R-HSA-168256 | Immune System |
| reactome | R-HSA-194138 | Signaling by VEGF |
| reactome | R-HSA-212436 | Generic Transcription Pathway |
| reactome | R-HSA-2219528 | PI3K/AKT Signaling in Cancer |
| reactome | R-HSA-3700989 | Transcriptional Regulation by TP53 |
| reactome | R-HSA-388841 | Costimulation by the CD28 family |
| reactome | R-HSA-389356 | CD28 co-stimulation |
| reactome | R-HSA-389357 | CD28 dependent PI3K/Akt signaling |
| reactome | R-HSA-4420097 | VEGFA-VEGFR2 Pathway |
| reactome | R-HSA-5218920 | VEGFR2 mediated vascular permeability |
| reactome | R-HSA-5633007 | Regulation of TP53 Activity |
| reactome | R-HSA-5663202 | Diseases of signal transduction |
| reactome | R-HSA-5674400 | Constitutive Signaling by AKT1 E17K in Cancer |
| reactome | R-HSA-6804757 | Regulation of TP53 Degradation |
| reactome | R-HSA-6806003 | Regulation of TP53 Expression and Degradation |
| reactome | R-HSA-73857 | RNA Polymerase II Transcription |
| reactome | R-HSA-74160 | Gene expression (Transcription) |
| reactome | R-HSA-9006925 | Intracellular signaling by second messengers |
| reactome | R-HSA-9006934 | Signaling by Receptor Tyrosine Kinases |
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD151 | CHM-1 | 3 |
| iGMDRD643 | MLN0128 | 1 |
| iGMDRD420 | Leucascandrolide A | 3 |
| iGMDRD781 | Sirolimus | 3 |
| iGMDRD741 | Cc-223 | 1 |
| iGMDRD698 | Neratinib | 2 |
| iGMDRD280 | CYTOCHALASIN B | 5 |
| iGMDRD297 | Austocystin D | 3 |
| iGMDRD952 | mTORC1/2 inhibitor | 2 |
| iGMDRD631 | Pandacostat | 1 |
| iGMDRD187 | BRD9876 | 1 |
| iGMDRD52 | Rotenone | 1 |
| iGMDRD318 | PAC-1 | 4 |
| iGMDRD68 | Paclitaxel | 1 |
| iGMDRD887 | Compound 23 citrate | 2 |
| iGMDRD399 | Selumetinib | 3 |
| iGMDRD871 | BRD6368 | 9 |
| iGMDRD414 | MST-312 | 3 |
| iGMDRD888 | Compound 44 | 3 |
| iGMDRD329 | Merck60 | 2 |
| iGMDRD246 | NPC26 | 2 |
| iGMDRD552 | AZD-1775 | 2 |
| iGMDRD64 | Parbendazole | 3 |
| iGMDRD384 | EHT-1864 | 1 |
| iGMDRD268 | Cerulenin | 2 |
| iGMDRD42 | Vorinostat | 3 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in RICTOR
CLASSFICATION
Copyright © 2018 Modellab | All Rights Reserved
Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.